Selumetinib (Koselugo)

Mechanism of action

Inhibits the enzyme MAPK kinase (MEK), specifically the MEK1 and MEK2 subtypes of the enzyme.

Preliminary data

While this drug has been mentioned as "promising" numerous times, there are no phase II or phase III studies that have been published thus far with a clear beneficial effect.